IMMUNEONCO-B AGM Endorses 2025 Financials, Reappoints Deloitte and Renews Dual Mandates

Bulletin Express

May 28

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) released the voting outcomes of its 28 May 2026 annual general meeting, where shareholders representing 208.98 million shares—48.43 % of the 431.51 million shares in issue—participated in person or by proxy. All eight ordinary and two special resolutions were approved.

Key approvals:

1. 2025 performance reports • Board, Supervisory Committee and Annual Report each secured 100 % support. • Final 2025 financial report and 2026 budget passed with 98.60 % in favour.

2. Capital allocation • 2025 Profit Distribution Plan received unanimous backing.

3. External auditor • Deloitte Touche Tohmatsu was re-appointed for 2026 with 98.61 % support; the Board is authorised to set remuneration.

4. Compensation • Directors’ and supervisors’ 2026 remuneration plans were both approved with full support.

5. Share mandates • General mandate to allot and issue new shares obtained 97.63 % approval. • H-share repurchase mandate passed with 100 % approval.

Computershare Hong Kong Investor Services acted as poll scrutineer. Eight of nine directors attended the meeting, which was chaired by Chairman and CEO Dr. Tian Wenzhi.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1183618518"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183618518\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183618518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183618518","market":"us","top_or_hot":-1,"title":"IMMUNEONCO-B AGM Endorses 2025 Financials, Reappoints Deloitte and Renews Dual Mandates","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) released the voting outcomes of its 28 May 2026 annual general meeting, where shareholders representing 208.98 million shares—48.43 % of the 431.51 million shares in issue—participated in person or by proxy. All eight ordinary and two special resolutions were approved.</p>\n<p>Key approvals:</p>\n<p>1. 2025 performance reports  \n   • Board, Supervisory Committee and Annual Report each secured 100 % support.  \n   • Final 2025 financial report and 2026 budget passed with 98.60 % in favour.</p>\n<p>2. Capital allocation  \n   • 2025 Profit Distribution Plan received unanimous backing.</p>\n<p>3. External auditor  \n   • Deloitte Touche Tohmatsu was re-appointed for 2026 with 98.61 % support; the Board is authorised to set remuneration.</p>\n<p>4. Compensation  \n   • Directors’ and supervisors’ 2026 remuneration plans were both approved with full support.</p>\n<p>5. Share mandates  \n   • General mandate to allot and issue new shares obtained 97.63 % approval.  \n   • H-share repurchase mandate passed with 100 % approval.</p>\n<p>Computershare Hong Kong Investor Services acted as poll scrutineer. Eight of nine directors attended the meeting, which was chaired by Chairman and CEO Dr. Tian Wenzhi.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B AGM Endorses 2025 Financials, Reappoints Deloitte and Renews Dual Mandates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B AGM Endorses 2025 Financials, Reappoints Deloitte and Renews Dual Mandates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-28 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) released the voting outcomes of its 28 May 2026 annual general meeting, where shareholders representing 208.98 million shares—48.43 % of the 431.51 million shares in issue—participated in person or by proxy. All eight ordinary and two special resolutions were approved.</p>\n<p>Key approvals:</p>\n<p>1. 2025 performance reports  \n   • Board, Supervisory Committee and Annual Report each secured 100 % support.  \n   • Final 2025 financial report and 2026 budget passed with 98.60 % in favour.</p>\n<p>2. Capital allocation  \n   • 2025 Profit Distribution Plan received unanimous backing.</p>\n<p>3. External auditor  \n   • Deloitte Touche Tohmatsu was re-appointed for 2026 with 98.61 % support; the Board is authorised to set remuneration.</p>\n<p>4. Compensation  \n   • Directors’ and supervisors’ 2026 remuneration plans were both approved with full support.</p>\n<p>5. Share mandates  \n   • General mandate to allot and issue new shares obtained 97.63 % approval.  \n   • H-share repurchase mandate passed with 100 % approval.</p>\n<p>Computershare Hong Kong Investor Services acted as poll scrutineer. Eight of nine directors attended the meeting, which was chaired by Chairman and CEO Dr. Tian Wenzhi.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1183618518","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183618518","pubTimestamp":1779969795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) released the voting outcomes of its 28 May 2026 annual general meeting, where shareholders representing 208.98 million shares—48.43 % of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B年度股东大会批准2025年财务状况、重新任命德勤并续签双重授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) released the voting outcomes of its 28 May 2026 annual general meeting, where shareholders representing 208.98 million shares—48.43 % of the 431.51 million shares in issue—participated in person or by proxy. All eight ordinary and two special resolutions were approved.\nKey approvals:\n1. 2025 performance reports  \n   • Board, Supervisory Committee and Annual Report each secured 100 % support.  \n   • Final 2025 financial report and 2026 budget passed with 98.60 % in favour.\n2. Capital allocation  \n   • 2025 Profit Distribution Plan received unanimous backing.\n3. External auditor  \n   • Deloitte Touche Tohmatsu was re-appointed for 2026 with 98.61 % support; the Board is authorised to set remuneration.\n4. Compensation  \n   • Directors’ and supervisors’ 2026 remuneration plans were both approved with full support.\n5. Share mandates  \n   • General mandate to allot and issue new shares obtained 97.63 % approval.  \n   • H-share repurchase mandate passed with 100 % approval.\nComputershare Hong Kong Investor Services acted as poll scrutineer. Eight of nine directors attended the meeting, which was chaired by Chairman and CEO Dr. Tian Wenzhi.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}